1. Search Result
Search Result
Results for "

Withanolide B

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

3

Peptides

3

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-129566

    ERK Wnt β-catenin RUNX Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects .
    Withanolide B
  • HY-P10928

    Transferrin Receptor Neurological Disease Cancer
    BCY17901 TFA is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 TFA inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 TFA can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
    BCY17901 TFA
  • HY-129566R

    Reference Standards ERK Wnt β-catenin RUNX Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Withanolide B (Standard) is the analytical standard of Withanolide B. This product is intended for research and analytical applications. Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects .
    Withanolide B (Standard)
  • HY-N10887

    GABA Receptor Neurological Disease
    Withasomniferolide B is a withanolide. Withasomniferolide B can be isolated from a GABAA receptor positive activator methanol extract of the roots of Withania somnifera .
    Withasomniferolide B
  • HY-P10928A

    Transferrin Receptor Neurological Disease Cancer
    BCY17901 is a potent irreversible transferrin receptor 1 (TfR1) inhibitor (Ki=12 nM). BCY17901 inhibits TfR1-mediated endocytosis and iron transport, and suppresses the proliferation of tumor cells dependent on iron metabolism. BCY17901 can be used in the research of solid tumors (such as breast cancer, glioblastoma) and neurodegenerative diseases .
    BCY17901
  • HY-P10319

    PKA Cardiovascular Disease Cancer
    RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .
    RI-STAD-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: